Thrombotic Thrombocytopenic Purpura Clinical Trial
Official title:
Interest of Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care: Multicentric Randomized Controlled Trial
Thrombotic Thrombocytopenic Purpura (TTP) is a potentially life-threatening thrombotic microangiopathy caused by a severe deficiency of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif member 13). Decreased ADAMTS13 activity leads to an accumulation of ultralarge von Willebrand factor (vWF) multimers which induce aggregation of platelets and microthrombi. These microthrombi may involve the brain, heart, kidneys and lead to life-threatening organ failures. In experimental models, magnesium sulfate increases cleavage of newly released vWF by ADAMTS13, decreases the endothelial secretion of ultralarge vWF and inhibits the interaction of vWF with platelets. In another thrombotic microangiopathy, magnesium sulfate has been shown to reduce the risk of seizures in women with severe pre-eclampsia. In analogy with its evidence-based therapeutic application in pre-eclampsia and based on a strong rationale for magnesium supplementation in TTP, we propose a phase 3, double blind, placebo controlled, and randomized study to evaluate the efficacy of magnesium sulfate in more rapidly restoring normal platelet counts as measure of prevention of further microvascular thrombosis in patients with Thrombotic Thrombocytopenic Purpura.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
| Recruiting |
NCT05785468 -
A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)
|
||
| Completed |
NCT04074187 -
A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
|
Phase 2/Phase 3 | |
| Terminated |
NCT00953771 -
Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)
|
Phase 2 | |
| Recruiting |
NCT01257269 -
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
|
||
| Not yet recruiting |
NCT05568147 -
Aspirin for Prophylaxis of TTP
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05468320 -
Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
|
Phase 3 | |
| Completed |
NCT00713193 -
Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)
|
Phase 3 | |
| Completed |
NCT00426686 -
ADAMTS13 in Thrombotic Thrombocytopenic Purpura
|
N/A | |
| Withdrawn |
NCT00251277 -
Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04588194 -
Romiplostim, Rituximab and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia
|
Phase 2 | |
| Completed |
NCT00907751 -
Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
|
Phase 2 | |
| Completed |
NCT03369314 -
Observational Study of the Use of octaplasLG®.
|
||
| Terminated |
NCT01938404 -
Octaplas Adult TTP Trial
|
||
| Recruiting |
NCT04981028 -
The ConNeCT Study: Neurological Complications of TTP
|
||
| Completed |
NCT02134171 -
Early Predictive Factors of Cardiac and Cerebral Involvement in TMA
|
N/A | |
| Recruiting |
NCT05389007 -
.German TTP-Registry (Thrombotic Thrombocytopenic Purpura)
|
||
| Withdrawn |
NCT02626663 -
The Role of Microparticles as a Biomarker
|
||
| Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
| Terminated |
NCT00593229 -
International Registry and Biorepository for TMA(Thrombotic Microangiopathy)
|
N/A |